MKS Inc. Common Stock
MKSI
$239.27
-10.49%
MKS Inc. is a foundational technology supplier to the semiconductor, electronics and packaging, and specialty industrial markets, delivering instruments, components, subsystems, process control systems, and specialty chemicals that improve process performance and productivity for leading-edge device manufacturing. The company operates through three divisions — Vacuum Solutions (VSD), Photonics Solutions (PSD), and Materials Solutions (MSD) — giving it a diversified, platform-like position across the semiconductor capital equipment supply chain rather than a single-product niche. The current investor narrative is dominated by a powerful cyclical recovery in semiconductor capital spending: revenue has re-accelerated to double-digit year-over-year growth, gross margins have begun to expand, and the stock has been one of the best performers in the technology hardware complex over the past year. At the same time, the shares have experienced a sharp multi-month drawdown from their summer highs, and the debate now centers on whether the AI-driven demand cycle can sustain the earnings ramp implied by consensus estimates or whether the stock has already discounted the upcycle.…
MKSI
MKS Inc. Common Stock
$239.27
Investment Opinion: Should I buy MKSI Today?
The synthesized recommendation is Buy, anchored by the analyst consensus rating of buy (mean 1.64) and an average target price of $417.57, which implies 56.2% upside from the current $267.31. The core thesis is that MKSI is in the early-to-mid stages of a cyclical earnings recovery, with revenue growth re-accelerating to 15.17% year-over-year and operating income up 55.9%, while the forward PE of 15.18x is undemanding relative to peers and the company's growth rate.
The supporting evidence is compelling: revenue has grown sequentially for four consecutive quarters, from $973 million in Q2 2025 to $1.078 billion in Q1 2026; operating margin expanded to 16.05% from 11.86% a year ago; net income rose 61.5% to $84 million; and the PEG ratio of 0.65 suggests the stock is inexpensive relative to expected growth. The forward PE of 15.18x compares favorably to many large-cap semiconductor equipment peers trading at 20–30x, and the price-to-sales ratio of 2.74x is well below the 10–14x levels seen in early 2026. While trailing free cash flow of $401 million is solid, the lumpiness in quarterly FCF is a concern.
The biggest risks that could invalidate this thesis are a stall in the semiconductor capex cycle, continued gross margin compression, and the company's elevated leverage. The rating would upgrade to a strong buy if gross margins stabilize above 45% and free cash flow converts more consistently, or downgrade to a hold if revenue growth decelerates below 10% or if operating margins fall back below 14%. Relative to its own history and peers, MKSI appears undervalued on a forward basis but fairly valued to slightly overvalued on trailing metrics, making it a compelling buy for investors with a medium-term horizon who can tolerate volatility.
Sign up to view all
MKSI 12-Month Price Forecast
MKSI presents a compelling medium-term opportunity as the semiconductor capital equipment cycle recovers, with revenue growth re-accelerating and operating leverage driving strong earnings growth. The forward valuation is undemanding at 15.18x earnings, and the analyst consensus target of $417.57 implies significant upside. However, the recent 24.85% three-month drawdown and gross margin compression highlight the risks of a cyclical slowdown. I would upgrade to high confidence if Q2 2026 results show revenue above $1.1 billion and gross margin stabilization above 43%. Conversely, a downgrade to neutral would be warranted if revenue growth falls below 10% or if free cash flow remains weak for another quarter.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on MKS Inc. Common Stock's 12-month outlook, with a consensus price target around $417.57 and implied upside of +74.5% versus the current price.
Average Target
$417.57
0 analysts
Implied Upside
+74.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$270 - $600
Analyst target range
Coverage is robust, with 14 analysts publishing estimates and a consensus recommendation of "buy" (recommendation mean of 1.64, where 1.0 is a strong buy). The average target price is $417.57, which implies roughly +56.2% upside from the current price of $267.31 — an unusually large gap that reflects both the severity of the recent selloff and analysts' confidence in the earnings recovery. Consensus estimated EPS averages $19.92 (range $19.03–$20.87) on estimated revenue of $6.71 billion (range $6.47–$6.95 billion), and the institutional ratings flow is uniformly constructive: Mizuho, Morgan Stanley, KeyBanc, Cantor Fitzgerald, BofA, Citigroup, and JPMorgan all carry Outperform/Buy/Overweight ratings as of mid-2026, with Wells Fargo the lone Equal Weight. The consensus clearly leans bullish, and the fact that no firm has downgraded despite the 25% three-month drawdown suggests analysts view the pullback as a buying opportunity rather than a fundamental deterioration. The target range is extremely wide — $270 at the low to $600 at the high — a spread of 122% of the current price that signals high uncertainty about the magnitude and duration of the semiconductor upcycle. The low target of $270 (essentially the current price) implies a scenario of flat-to-modest earnings, margin pressure, or a stalled capex cycle, while the high target of $600 assumes aggressive multiple expansion, accelerating AI-driven demand, and successful deleveraging that lifts both earnings and the valuation multiple. The tight clustering of recent ratings (all reaffirmations rather than upgrades or downgrades) indicates analysts are in a holding pattern awaiting the next earnings print to validate the recovery; with a short ratio of 4.42 and a beta of 1.973, the wide target dispersion and high short interest create the potential for sharp moves in either direction depending on whether results confirm or refute the bullish consensus.
Bulls vs Bears: MKSI Investment Factors
The bull case rests on a clear cyclical recovery: revenue growth has re-accelerated to 15.17% year-over-year, operating income is up 55.9%, and the forward PE of 15.18x is undemanding if consensus EPS of $19.92 is met. Analyst sentiment is overwhelmingly positive, with a buy consensus and a $417.57 average target implying 56.2% upside. However, the bear case is equally compelling: the stock has suffered a 24.85% three-month drawdown, gross margins have compressed 625 basis points year-over-year, and leverage remains elevated with interest coverage of only 3.8x. The most important tension is whether the AI-driven semiconductor capex cycle can sustain the earnings ramp that consensus expects; if it does, the stock is significantly undervalued, but if the cycle stalls, the current price could be vulnerable given the high beta of 1.973 and the wide target dispersion. On balance, the evidence slightly favors the bulls because the fundamental momentum is improving and the forward valuation is reasonable, but the technical breakdown and margin pressure warrant caution.
Bullish
- Revenue growth re-accelerating: Q1 2026 revenue of $1.078 billion grew 15.17% year-over-year, up from roughly 4% growth in mid-2025. The sequential progression from $973 million in Q2 2025 to $1.078 billion in Q1 2026 confirms a broadening cyclical recovery.
- Operating leverage driving earnings: Operating income surged 55.9% year-over-year to $173 million in Q1 2026, lifting operating margin to 16.05% from 11.86% a year earlier. Net income rose 61.5% to $84 million, demonstrating powerful incremental margins despite gross margin compression.
- Forward PE discount to peers: MKSI trades at a forward PE of 15.18x versus many large-cap semiconductor equipment peers at 20–30x, and its PEG ratio of 0.65 suggests the stock is inexpensive relative to expected growth. This discount provides valuation support if consensus EPS of $19.92 is achieved.
- Analyst targets imply large upside: The consensus average target price of $417.57 implies 56.2% upside from the current $267.31, with 14 analysts and a recommendation mean of 1.64 (buy). No downgrades have occurred despite the 24.85% three-month decline, suggesting the selloff is viewed as a buying opportunity.
Bearish
- Severe momentum breakdown: The stock is down 24.85% over three months and 12.88% over one month, with relative strength versus SPY at -27.89 and -11.82 points respectively. This sharp deceleration from a 130.44% one-year gain signals a momentum unwind that may not be complete.
- Gross margin compression: Gross margin fell to 41.19% in Q1 2026 from 47.44% in Q1 2025, a 625 basis point decline. This reflects unfavorable product mix and higher materials costs, and if sustained, could limit the earnings ramp implied by consensus.
- Elevated leverage and weak coverage: Debt-to-equity stands at 1.73x with total debt to capitalization of 60.4%, and interest coverage is only about 3.8x. The company relies on continued earnings growth to deleverage, making the durability of the semiconductor upcycle critical.
- Lumpy and weak free cash flow: Trailing-twelve-month free cash flow is $401 million, but Q1 2026 FCF was only $28 million as working capital absorbed $134 million. This volatility raises questions about the quality of earnings and the ability to fund operations and debt service.
MKSI Technical Analysis
MKSI is in a powerful longer-term uptrend that has recently entered a corrective phase. The stock is up 130.44% over the past year versus a 16.22% gain for SPY, an extraordinary 114.22 percentage point relative-strength advantage, and it remains up 58.77% year-to-date. However, at $267.31 the shares sit only about 45.6% of the way up the 52-week range of $114.36–$447.62, having surrendered a large portion of their earlier gains; this positioning is neither a clean momentum breakout nor a deep-value falling knife, but rather a high-beta name in a volatile mid-cycle consolidation. The 1-month change of -12.88% and 3-month change of -24.85% show that short-term momentum has decisively decelerated and now diverges sharply from the still-strong 1-year trend, a classic signature of a momentum unwind or mean-reversion phase within a broader uptrend. Relative strength versus SPY is -11.82 points over 1 month and -27.89 points over 3 months, confirming meaningful recent underperformance, while the 6-month change of +25.23% and relative strength of +9.83 points show the intermediate trend has not fully broken down. The most recent session did bounce 2.09% off the prior close of $261.84, suggesting buyers are beginning to defend the low-$260s. Key support sits at the 52-week low of $114.36, with the more immediately relevant support zone around the recent $246–$256 lows; resistance is defined by the 52-week high of $447.62, with intermediate resistance near the $320–$345 area where the stock repeatedly stalled in July and August. A breakout above that intermediate band would signal the correction is over and the primary uptrend has resumed, while a breakdown below $246 would open the door to a retest of the $220–$230 region. With a beta of 1.973, MKSI is nearly twice as volatile as the market, and the -44.6% maximum drawdown underscores that position sizing and stop discipline are critical; a short ratio of 4.42 also indicates a meaningful short base that could amplify upside squeezes on positive catalysts.
Beta
1.97
1.97x market volatility
Max Drawdown
-46.2%
Largest decline past year
52-Week Range
$115-$448
Price range past year
Annual Return
+107.9%
Cumulative gain past year
| Period | MKSI Return | S&P 500 |
|---|---|---|
| 1m | -23.0% | -2.0% |
| 3m | -34.7% | +1.4% |
| 6m | +2.5% | +15.0% |
| 1y | +107.9% | +15.7% |
| ytd | +42.1% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MKSI Fundamental Analysis
MKSI's revenue trajectory has clearly re-accelerated. The most recent quarter (Q1 2026, ended 2026-03-31) delivered revenue of $1.078 billion, up 15.17% year-over-year from $936 million in Q1 2025, and up sequentially from $1.033 billion in Q4 2025. The multi-quarter trend is one of steady acceleration: revenue progressed from $973 million in Q2 2025 to $988 million in Q3 2025 to $1.033 billion in Q4 2025 to $1.078 billion in Q1 2026, with the year-over-year growth rate inflecting from roughly 4% in mid-2025 to over 15% in the latest quarter. Segment disclosure shows the Product business generated $954 million versus $124 million for Service, meaning the cyclical hardware/product side is the dominant growth engine and the primary swing factor for the investment case. Profitability is solid and improving. Q1 2026 net income was $84 million on a 7.79% net margin, with gross profit of $444 million and a 41.19% gross margin; operating income of $173 million equates to a 16.05% operating margin, up from 11.86% in Q1 2025. Gross margin has compressed modestly from the 46.6–47.4% levels seen in mid-2025 (Q1 2026 gross margin of 41.19% versus 47.44% in Q1 2025), likely reflecting product mix and higher materials costs, but operating leverage from SG&A and R&D discipline has more than offset that, driving operating income up 55.9% year-over-year. Net income has grown from $52 million in Q1 2025 to $84 million in Q1 2026, a 61.5% increase, confirming genuine earnings momentum. The balance sheet carries meaningful but manageable leverage. Debt-to-equity stands at 1.73x, with total debt to capitalization of 60.4% and long-term debt to capitalization of 48.5%; the current ratio of 2.71x and quick ratio of 1.71x indicate adequate near-term liquidity. Free cash flow on a trailing-twelve-month basis is $401 million, though quarterly FCF has been lumpy — $28 million in Q1 2026 versus $91 million in Q4 2025 and $146 million in Q3 2025 — as working capital absorbed $134 million in the latest quarter. ROE of 10.85% and ROA of 5.02% are respectable but not exceptional, and interest coverage of roughly 3.8x leaves limited cushion; the company is generating enough cash to fund operations and modest capex ($25 million in Q1 2026) but relies on continued earnings growth to deleverage, making the durability of the semiconductor upcycle central to the credit and equity story.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+15.2%
YoY Comparison
Gross Margin
41.2%
Latest Quarter
Free Cash Flow
$401000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MKSI Overvalued?
Because MKSI is profitable — Q1 2026 net income of $84 million and trailing EPS of $0.027 (reflecting GAAP distortions) — the PE ratio is the appropriate primary metric, though the trailing figure is distorted by non-cash items. The trailing PE of 36.4x versus a forward PE of 15.18x implies the market expects earnings to roughly double, consistent with consensus estimated EPS of $19.92 for the forward period; that enormous gap between trailing and forward multiples signals the market is pricing in a full cyclical earnings recovery rather than steady-state growth. On a price-to-sales basis, MKSI trades at 2.74x, and EV/EBITDA of 17.18x and EV/Sales of 4.90x provide cross-checks on the valuation. Relative to the broader semiconductor equipment and hardware sector, MKSI's forward PE of 15.18x screens at a discount to many large-cap peers that often trade in the 20–30x forward range, though the trailing PE of 36.4x and PEG of 0.65 complicate the comparison; the PEG below 1.0 suggests the stock is inexpensive relative to its expected growth rate. The premium/discount assessment is nuanced: MKSI's 41.19% gross margin and 16.05% operating margin are respectable but below the highest-quality analog and lithography names, which justifies some discount, while its 15%+ revenue growth and 61% net income growth argue the discount is too wide. Historically, MKSI's PE has ranged from the low teens (2021–2022, around 11–16x) to distressed levels above 90x during the 2023–2024 semiconductor downturn; the current trailing PE of 36.4x is elevated versus the 2021–2022 norm but well below the trough-earnings distortions of 2023–2024. The price-to-book ratio of 3.96x is near the middle of its historical band (roughly 1.2x at the 2022 low to 5.5x in early 2026), and the price-to-sales ratio of 2.74x is far below the 10–14x levels recorded in early 2026, reflecting both the share price decline and revenue growth. Net-net, the stock appears to be pricing in a successful earnings recovery but not an extreme one; the forward multiple is undemanding if consensus EPS is achieved, but the trailing multiple leaves little room for execution disappointment.
PE
36.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 11x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.2x
Enterprise Value Multiple
Investment Risk Disclosure
MKSI's financial risk profile is characterized by meaningful leverage and uneven cash generation. Debt-to-equity of 1.73x and total debt to capitalization of 60.4% indicate a balance sheet that is manageable but not fortress-like, and interest coverage of roughly 3.8x leaves limited cushion if earnings falter. Free cash flow is lumpy, with Q1 2026 FCF of just $28 million versus $146 million in Q3 2025, as working capital absorbed $134 million. Additionally, gross margin compression from 47.44% in Q1 2025 to 41.19% in Q1 2026 raises the risk that the earnings recovery may not translate into proportional cash flow if input costs remain elevated.
Market and competitive risks are significant given MKSI's high beta of 1.973 and its exposure to the cyclical semiconductor capital equipment sector. The stock has already demonstrated a maximum drawdown of -44.6%, and its 24.85% three-month decline shows how quickly sentiment can reverse. Valuation risk is twofold: the trailing PE of 36.4x is elevated relative to the 2021–2022 range of 11–16x, and the forward PE of 15.18x relies on consensus EPS of $19.92, which assumes a full cyclical recovery. Competitive threats from larger peers like Applied Materials and Lam Research, as well as potential share loss in vacuum and photonics solutions, could pressure margins. Regulatory risks, particularly export controls to China, which is a significant revenue source, could also disrupt demand.
In a worst-case scenario, a stall in the semiconductor capex cycle would cause earnings to miss consensus, leading to multiple compression and a decline toward the 52-week low of $114.36 or the analyst low target of $270. From the current price of $267.31, a drop to $114.36 would represent a loss of approximately 57.2%. Even a retest of the recent support zone around $246–$256 would be a 4–8% decline, but a more severe downturn could see the stock fall to the $220–$230 region, a 14–18% loss. Given the high short interest and beta, such a move could be swift and amplified.
FAQ
The most severe risk is a cyclical downturn in semiconductor capital spending, which could cause revenue growth to decelerate and earnings to miss consensus. Financial risks include elevated leverage with a debt-to-equity of 1.73x and interest coverage of only 3.8x, leaving limited cushion if earnings decline. Operational risks center on gross margin compression, which fell to 41.19% in Q1 2026 from 47.44% a year earlier, potentially limiting profitability. Market risks include the stock's high beta of 1.973, which amplifies drawdowns, and a maximum historical drawdown of -44.6%. Additionally, regulatory risks such as export controls to China could disrupt a significant portion of revenue.
Our 12-month forecast presents three scenarios: a bull case with 30% probability targeting $450–$600, a base case with 50% probability targeting $380–$450, and a bear case with 20% probability targeting $220–$270. The base case is most likely, assuming revenue grows 12–15% year-over-year and consensus EPS of $19.92 is achieved, which would support a stock price near the analyst average target of $417.57. The key assumption is that the semiconductor capex cycle continues to recover without a major slowdown. The bull case requires accelerating AI-driven demand and margin expansion, while the bear case would be triggered by a capex stall and further margin compression.
MKSI appears undervalued on a forward basis but fairly valued on trailing metrics. The forward PE of 15.18x is a discount to many semiconductor equipment peers trading at 20–30x, and the PEG ratio of 0.65 suggests the stock is cheap relative to expected growth. However, the trailing PE of 36.4x is elevated compared to the 2021–2022 range of 11–16x, and the price-to-sales ratio of 2.74x is above the historical low but well below the 10–14x seen in early 2026. The market is pricing in a successful earnings recovery, with consensus EPS of $19.92 representing a near-doubling from trailing levels. If that recovery materializes, the stock is undervalued; if it stalls, the trailing multiple leaves little room for error.
From a risk/reward perspective, MKSI offers a favorable setup for investors with a medium-term horizon. The stock trades at $267.31, implying 56.2% upside to the analyst average target of $417.57, and the forward PE of 15.18x is well below the sector average. However, the biggest downside risk is a stall in the semiconductor capex cycle, which could send the stock back toward its 52-week low of $114.36, a 57% decline. Given the high beta of 1.973 and the recent 24.85% three-month drawdown, this is not a low-risk investment. It is a good buy for investors who believe the AI-driven demand cycle will sustain earnings growth and who can tolerate volatility, but position sizing should be conservative.
MKSI is better suited for medium-to-long-term investment rather than short-term trading, given its high beta of 1.973 and significant volatility. The stock has a maximum drawdown of -44.6% and a 24.85% three-month decline, making short-term timing difficult. The company pays a small dividend with a yield of 0.55% and a payout ratio of 20%, indicating a modest income component. Earnings visibility is improving with the cyclical recovery, but the wide analyst target range of $270 to $600 reflects uncertainty. A suggested minimum holding period is 12–18 months to allow the semiconductor upcycle to play out and for the forward earnings recovery to be realized.